or Try an Advanced Search...

    Technical Analysis for JAGX - Jaguar Animal Health, Inc.

    Grade Last Price % Change Price Change
    F 1.06 0.95% 0.01
    JAGX closed up 0.95 percent on Friday, November 1, 2024, on 42 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Nov 12
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical JAGX trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 0.95%
    Lower Bollinger Band Walk Weakness 0.95%
    Down 3 Days in a Row Weakness 0.95%
    Lower Bollinger Band Touch Weakness 0.95%
    Older End-of-Day Signals for JAGX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 21 hours ago
    Up 1% about 24 hours ago
    Fell Below Lower Bollinger Band 2 days ago
    Fell Below Previous Day's Low 2 days ago
    Down 2 % 2 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    JAGX Chart by TradingView
    Basic chart:

    Profile

    Jaguar Animal Health, Inc. Description

    Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Gastrointestinal Animal Health Dog Gastroenterology Prescription Drugs Colitis Drug Products Diarrhea Gastrointestinal Tract Gastrointestinal Products

    Is JAGX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 16 Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
    Oct 11 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Oct 10 Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
    Oct 9 Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...
    Oct 8 Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
    Oct 2 Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup
    Oct 1 Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
    Sep 26 Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients ...
    Sep 25 Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
    Sep 24 Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
    See more JAGX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 30.864
    52 Week Low 0.9501
    Average Volume 245,984
    200-Day Moving Average 4.59
    50-Day Moving Average 1.17
    20-Day Moving Average 1.18
    10-Day Moving Average 1.11
    Average True Range 0.07
    RSI (14) 35.48
    ADX 17.17
    +DI 16.39
    -DI 20.50
    Chandelier Exit (Long, 3 ATRs) 1.19
    Chandelier Exit (Short, 3 ATRs) 1.23
    Upper Bollinger Bands 1.34
    Lower Bollinger Band 1.02
    Percent B (%b) 0.13
    BandWidth 27.16
    MACD Line -0.05
    MACD Signal Line -0.03
    MACD Histogram -0.0134
    Fundamentals Value
    Market Cap 53.8 Million
    Num Shares 50.8 Million
    EPS -0.87
    Price-to-Earnings (P/E) Ratio -1.22
    Price-to-Sales 0.46
    Price-to-Book 3.12
    PEG Ratio -0.02
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.09
    Resistance 3 (R3) 1.09 1.08 1.09
    Resistance 2 (R2) 1.08 1.07 1.08 1.08
    Resistance 1 (R1) 1.07 1.07 1.07 1.07 1.08
    Pivot Point 1.06 1.06 1.06 1.06 1.06
    Support 1 (S1) 1.05 1.05 1.05 1.05 1.04
    Support 2 (S2) 1.04 1.05 1.04 1.04
    Support 3 (S3) 1.03 1.04 1.04
    Support 4 (S4) 1.03